drugset / Trial / NCT01475383

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

NCT01475383 ↗

Phase 2 Withdrawn Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of an investigational compound designated PF-03654746 compared to placebo in the treatment of adults with Tourette's Syndrome. The study will also explore the pharmacokinetics of PF-03654746 in adults with Tourette's Syndrome.

Timeline

Start
2012-04
Primary completion
2012-04
Completion
2012-04

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator PF-03654746 Small molecule 1 mg —
Comparator PF-03654746 Small molecule 2 mg —

Indications